生物力学计算机断层扫描在转移性激素敏感性前列腺癌骨折风险分类中的验证
这项多中心回顾性队列研究纳入91例转移性激素敏感性前列腺癌患者,评估生物力学计算机断层扫描(BCT)与双能X线吸收测定法(DXA)骨密度相关性及BCT指标与后续骨折的关联。BCT与DXA股骨颈骨密度T评分强相关(R²=0.93),基线BCT骨密度较低与病理性骨折风险升高相关(OR 1.80,95%CI 1.10-3.25,p=0.03),BCT还识别出9例(9.9%)有抗骨吸收治疗指征的患者。
要点
- BCT与DXA评估的股骨颈骨密度T评分强相关(R²=0.93)。
- 基线BCT骨密度较低与病理性骨折风险升高相关(OR 1.80,p=0.03)。
- BCT识别出9例(9.9%)有抗骨吸收治疗指征者,其中4例(44%)未治疗。
核心结论
- 在转移性激素敏感性前列腺癌患者中,BCT评估与DXA强相关,可预测后续病理性骨折,并识别出更多有抗骨吸收治疗指征的男性。
研究设计与样本
- 多中心回顾性队列研究,纳入2013年至2020年间91例转移性激素敏感性前列腺癌患者,均在ADT开始前48周内及ADT开始后48-96周随访期间接受过腹部/盆腔CT或PET/CT检查。
主要发现
- 中位随访82周期间,17例(18.6%)发生病理性骨折,15例(16.5%)发生非病理性骨折。
- BCT与DXA评估的股骨颈骨密度T评分强相关(R²=0.93)。
- 基线CT上较低的BCT骨密度与病理性骨折风险升高相关(OR 1.80,95%CI 1.10-3.25,p=0.03)。
- 较低的股骨强度与病理性骨折风险升高呈边缘关联(OR 1.63,95%CI 0.99-2.71,p=0.06)。
- BCT骨密度(OR 1.52,95%CI 0.95-2.63,p=0.11)和强度(OR 1.14,95%CI 0.75-1.80,p=0.57)与非病理性骨折均无关联。
关键数值与推荐
- BCT识别出9例(9.9%)符合抗骨吸收治疗指征的男性,其中4例(44%)未接受治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括骨折数量少,导致检测骨折关联的效力较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend dual-energy x-ray absorptiometry (DXA) screening to assess fracture risk and benefit from antiresorptive therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC) on androgen deprivation therapy (ADT). However, <30% of eligible patients undergo DXA screening. Biomechanical computed tomography (BCT) is a radiomic technique that measures bone mineral density (BMD) and bone strength from computed tomography (CT) scans. OBJECTIVE: To evaluate the (1) correlations between BCT- and DXA-assessed BMD, and (2) associations between BCT-assessed metrics and subsequent fracture. DESIGN, SETTING, AND PARTICIPANTS: A multicenter retrospective cohort study was conducted among patients with mHSPC between 2013 and 2020 who received CT abdomen/pelvis or positron emission tomography/CT within 48 wk before ADT initiation and during follow-up (48-96 wk after ADT initiation). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used univariate logistic regression to assess the associations between BCT measurements and the primary outcomes of subsequent pathologic and nonpathologic fractures. RESULTS AND LIMITATIONS: Among 91 eligible patients, the median ([interquartile range) age was 67 yr (62-75), 44 (48.4%) were White, and 41 (45.1%) were Black. During the median follow-up of 82 wk, 17 men (18.6%) developed a pathologic and 15 (16.5%) a nonpathologic fracture. BCT- and DXA-assessed femoral-neck BMD T scores were strongly correlated (R2 = 0.93). On baseline CT, lower BCT-assessed BMD (odds ratio [OR] 1.80, 95% confidence interval or CI [1.10, 3.25], p = 0.03) was associated with an increased risk of a pathologic fracture. Lower femoral strength (OR 1.63, 95% CI [0.99, 2.71], p = 0.06) was marginally associated with an increased risk of a pathologic fracture. Neither BMD (OR 1.52, 95% CI [0.95, 2.63], p = 0.11) nor strength (OR 1.14, 95% CI [0.75, 1.80], p = 0.57) was associated with a nonpathologic fracture. BCT identified nine (9.9%) men eligible for antiresorptive therapy, of whom four (44%) were not treated. Limitations include low fracture numbers resulting in lower power to detect fracture associations. CONCLUSIONS: Among men diagnosed with mHSPC, BCT assessments were strongly correlated with DXA, predicted subsequent pathologic fracture, and identified additional men indicated for antiresorptive therapy. PATIENT SUMMARY: We assess whether biomechanical computer tomography (BCT) from routine computer tomography (CT) scans can identify fracture risk among patients recently diagnosed with metastatic prostate cancer. We find that BCT and dual-energy x-ray absorptiometry-derived bone mineral density are strongly correlated and that BCT accurately identifies the risk for future fracture. BCT may enable broader fracture risk assessment and facilitate timely interventions to reduce fracture risk in metastatic prostate cancer patients.
引用
- Lin JK, Hearn CM, Getzen E, et al. Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer. Eur Urol Oncol. 2023. PMID: 37926618. doi:10.1016/j.euo.2023.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。